Pain under attack: Explosion in biotechnology drugs focuses on arthritis
Article Abstract:
Immunex is waiting for FDA approval for a drug called Enbrel that relieves the symptoms of rheumatoid arthritis. Drawbacks are that long-term effects are not known and treatment will cost the patient $5,000-$10,000 per year; also, patients will have to self-inject the medication twice a week. Another hopeful is a pill called Arava from Hoechst Marion Roussel. There are several others close behind which are all treatments but not cures. Nevertheless, doctors and patients alike are pleased for the relief they will bring possibly 2.5 million people. Research on the immune system in recent years is the reason for the discoveries; rheumatoid arthritis is a disease that causes the body to attack and destroy its own joint linings.
Comment:
Biotech firm has a drug awaiting FDA approval that will help rheumatoid arthritis sufferers
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
F.D.A. panel recommends clearing genetic drug
Article Abstract:
A Food and Drug Administration (FDA) advisory committee called for the approval of the first drug that utilizes a new technology which prevents genes from functioning. The Isis Pharmaceuticals Inc.'s drug is a treatment for a viral infection that can lead to blindness in AIDS-infected people. The FDA normally adheres to the recommendations of advisory panels. The drug technology is called anti-sense.
Comment:
FDA advisory committee approves first drug to utilize a new technology that prevents genes from functioning
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Weight-loss drug shows some success in humans
Article Abstract:
Scientists believe that Amgen Inc.'s anti-obesity drug helped bring about weight-loss in humans. The drug had previously shown that it was effective in reducing body fat in mice. The results could end doubts that the leptin drug can produce weight-loss in humans. However, the results also show that leptin may not be a certain treatment for obesity.
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Managing innovation in public services: European and international experience. Delivering the message in challenging times: the relative effectiveness of different forms of communicating change to a dispersed and part-time workforce
- Abstracts: Pet project: Biotechs switch from drugs for man to drugs for man's best friends. FDA allows large-scale trial of AIDS vaccine
- Abstracts: DuPont puts stock in global security force. DuPont Merck sued over licensing deal. DuPont buys out Merck
- Abstracts: Lehman, Morgan Stanley post record for quarterly profits on merger boom. Merrill is in talks about acquiring Midland Walwyn
- Abstracts: Phone giant to acquire Bay Networks: Northern Telecom set to pay $9.1 billion. A British phone company looks to America